Eli Lilly and Co (BSP:LILY34)
R$ 154 -1.68 (-1.08%) Market Cap: 4.43 Tn Enterprise Value: 4.59 Tn PE Ratio: 86.21 PB Ratio: 50.39 GF Score: 77/100

Q4 2022 Eli Lilly and Co Earnings Call Transcript

Feb 02, 2023 / 03:00PM GMT
Release Date Price: R$55.56 (-4.02%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2022 Earnings Conference Call. (Operator Instructions)

And as a reminder, today's conference is being recorded. I would now like to turn the conference over to our host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.

Joe Fletcher
Eli Lilly and Company - VP of IR

Thank you, Lois. Good morning, and thank you all for joining us for Eli Lilly and Company's Q4 2022 Earnings Call. I'm Joe Fletcher. And joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Anat Ashkenazi, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific and Medical Officer; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, CEO of Loxo@Lilly; Mike Mason, President of Lilly Diabetes; and Patrik Jonsson, President of Lilly Immunology and Lilly USA. We're also joined by Mike Sprengnether, Kento Ueha and Lauren Zierke from the Investor Relations team.

During this conference call, we anticipate making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot